Hoyeraal-Hreidarsson syndrome (HHS, OMIM 500545) is a multisystem disease believed to represent a severe variant of dyskeratosis congenita (DC, OMIM 305000). 1 We report the case of a 40-month-old girl with classical features of HHS, including cerebellar hypoplasia, oral ulceration and BM failure. She is the 19th case of HHS and only the 4th female reported in the medical literature. She received an unrelated cord stem cell transplant with a fludarabinebased reduced-intensity conditioning (RIC) regime. To the best of our knowledge, she is only the fourth HHS patient to receive a haematopoietic stem cell transplantation (HSCT). Besides reactivation of CMV infection, there was minimal regimen-related toxicity associated with the stem cell transplant. This case highlights the classic features of HHS, the most likely locus of heterogeneity associated with HHS and the importance of considering the diagnosis before transplant.
Hoyeraal-Hreidarsson syndrome is a severely progressive multisystem disorder characterized by intrauterine growth retardation, microcephaly, cerebellar hypoplasia, mental retardation, oral aphthous ulcers, immune deficiency and aplastic anaemia. [1] [2] [3] [4] HHS creates significant mortality and morbidity, with BM failure and immunodeficiency being the most serious manifestation of the condition, occurring in over 80% of patients. The natural history of HHS is that of death secondary to complications of BM failure or infection that usually occurs in the first decade of life. 5 The patient reported here was the only child to nonconsanguineous Caucasian Australian parents. Gross motor and fine motor delay and ataxia became evident during the first 2 years of life. Persistent oral ulceration began at 22 months of age. Cerebellar hypoplasia was detected on a magnetic resonance imaging scan at 24 months of age.
At 30 months of age, thrombocytopaenia was diagnosed during the treatment for an intercurrent respiratory illness. A BM aspirate at this time revealed a hypocellular marrow consistent with trilineage BM failure. The coding regions for DKC1 and TERC, in DNA extracted from peripheral blood, were screened for mutations by denaturing HPLC and they failed to identify any mutations.
Immunological work up showed normal Ig and complement levels. T-and B-cell subsets were within normal reference ranges. Stimulation with phytohaemagglutinin and DHR-123-oxidative burst was normal. There was no increase in chromosomal breakage with diepoxybutane. In both peripheral and BM chromosome analyses, an abnormal cytogenetic clone was not detected.
Owing to progressive marrow failure and no matched related or unrelated donor being available, an unrelated cord blood transplant was performed. Following local Human Research Ethics Committee approval and with informed consent from the family, the fludarabine-based RIC regimen reported by Barker et al. 6 was used as follows: fludarabine, 40 mg/m 2 once daily i.v. on days -6 to -2 (total five doses); CY, 50 mg/kg daily i.v. on day À6 (total one dose); and TBI on day -1 (200 cGy Â 1 fraction). Antithymocyte globulin (equine) (ATGAM), 15 mg/kg twice daily i.v., was administered for 3 days (total six doses). The unrelated cord unit was an HLA 5/6 match with total nucleated cell and CD34 doses of 11.5 Â 10 7 /kg and 2.6 Â 10 5 /kg recipient body weight, respectively. The patient received G-CSF (5 mcg/kg daily) after transplantation until neutrophil engraftment.
GVHD prophylaxis consisted of CYA and mycophenolate. Myeloid engraftment defined as an absolute neutrophil count of 40.5 Â 10 9 /l for 43 days occurred on day þ 13, and platelet engraftment defined as a count of 450 Â 10 9 /l for 43 days without support occurred on day þ 45. The last packed RBC transfusion was given on day þ 28. Donor alleles were identified on engraftment studies performed by PCR for variable nucleotide tandem repeats (VNTRs) of the apolipoprotein B gene at day þ 34 with complete donor chimerism by day þ 100. Grade 2 GVHD of the skin and the gastrointestinal tract was confirmed on biopsies at day þ 25. This responded well to treatment with prednisolone.
The patient developed CMV reactivation on day 47 and on day 145 post transplant, as detected by rising CMV DNA titres (PCR). Both of these episodes were successfully treated with ganciclovir. The patient is currently 2 years post transplant with ongoing steroiddependent chronic GVHD of the skin and the gastrointestinal tract. She is continuing to progress in speech and motor developmental abilities and is attending a special needs preschool.
This patient displayed features consistent with a diagnosis of HHS, including intrauterine growth retardation, cerebellar hypoplasia, leukoplakia, developmental delay and aplastic anaemia. HHS and DC exhibit clinical and genetic heterogeneity with more than one locus implicated. Vulliamy et al. 4 report that almost 50% of patients with DC and HHS do not harbour a mutation of the DKC1 gene. Clear genotype-phenotype correlations are yet to emerge. However, null mutations have not been described, suggesting that this would be lethal. 7 Mutations in the genes responsible for X-linked and autosomal-dominant DC (DKC1 and TERC, respectively) have not been identified in females with HHS, suggesting that other loci are involved.
Dyskeratosis congenita is principally a disease of telomere maintenance. 7 Telomerase function is important in development, differentiation and activation of human lymphocytes. An increased in vitro sensitivity to radiation and alkylating agent in circulating lymphocytes and fibroblasts was demonstrated in a 7-year-old HHS boy. 8 This was correlated to telomere shortening. BMT using conventional conditioning regimes in DC patients have been associated with high mortality, particularly related to pulmonary and vascular complications. 8 This highlights the importance of making a correct diagnosis with the subsequent use of a RIC regimen.
We were able to identify only three HHS patients recorded in the literature who received a BMT. 1, 7, 8 Cossu et al.
7 chose a non-BU, non-TBI-containing regimen consisting of fludarabine, rabbit antithymocyte globulin and low-dose melphalan. This particular patient encountered prompt and sustained engraftment, from an HLAmatched elder sibling donor, at the time of publication 1-year post-BMT. 7 Knight et al. 1 report the use of an unrelated BMT in a 23-month-old boy; unfortunately, no information was provided regarding the conditioning regimen. At the time of publication, this patient was still alive 37 months post-BMT and experiencing significant medical and developmental complications of the underlying condition and the immune reconstitution process. 1 M'kacher et al. 8 reported the sibling matched transplantation in a 7-year-old boy after a chemotherapy conditioning regime of CY and fludarabine. No information was provided regarding the outcome of this procedure.
For this patient, this RIC regime was safe with minimal regimen related toxicity. Patients receiving highly immunosuppressive RIC regimens (particularly those containing fludarabine regimens) may be prone to an increased incidence of viral infections such as CMV and EBV. 9 However, with early detection and treatment, death due to reactivation can be avoided.
In conclusion, we report the 19th case of HHS and only the 4th female to be reported in the medical literature. 10, 11 To the best of our knowledge, she is only the fourth HHS patient to receive a HSCT. The high morbidity and mortality secondary to BM failure and immunodeficiency requires the consideration of HSCT.
